ISRCTN13390479进行中（未招募）Unknown
Analysis of proton versus photon radiotherapy in oligodendroglioma and assessment of cognitive health
niversity of Leeds0 个研究点目标入组 246 人开始时间: 2023年3月21日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 246
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically proven diagnosis of oligodendroglioma (ODG) with 1p19q co-deletion and isocitrate dehydrogenase (IDH) mutation
- •2. Randomisation must be performed within 28 days of the magnetic resonance imaging (MRI) that leads to the decision that radiotherapy (RT) is required at that point in time. Outside of 28 days, an updated MRI is required to serve as a contemporaneous baseline scan to assess response to further treatment.
- •3. Karnofsky Performance Status (KPS) =70%.
- •4. Adequate wound healing and recovery if recent surgery.
- •5. Suitable to complete baseline neurocognitive testing (No access to translated tests, can only be administered in English).
- •6. Patients of childbearing potential should be asked to confirm that they are not pregnant to confirm trial eligibility. Formal Pregnancy testing should be performed if there is any doubt as to pregnancy status or if felt appropriate, including in circumstances such as irregular periods, unprotected sexual intercourse since the last menstrual period, missed contraceptive pill or antibiotics during the last menstrual cycle or failure of barrier contraception.
- •7. Fertile participants, born male, must agree to practice methods of contraception that are considered medically acceptable for the duration of RT, adjuvant chemotherapy and for 6 months post-end of treatment if sexually active with a person of child-bearing potential.
- •8. Able to swallow oral medication.
- •9. Able to provide study-specific informed consent.
- •10. Age 25 or above at the point of starting RT treatment.
- •11. No known haematological, renal or hepatic impairments making PCV chemotherapy inappropriate
排除标准
- •1. Pregnancy (positive pregnancy test) or lactating.
- •2. Prior cranial or head and neck radiotherapy (RT).
- •3. Any previous chemotherapy for the treatment of oligodendroglioma (ODG).
- •4. Comorbid neurodegenerative diseases that influence neurocognitive function (NCF).
- •5. Severe active co-morbidity making patient unsuitable for RT and/ or adjuvant chemotherapy (e.g., uncontrolled diabetes, uncontrolled hypertension).
- •6. Leptomeningeal disease.
- •7. Spinal or infratentorial disease.
- •8. Another currently active malignancy or another malignancy within the last 3 years.
- •9. Any contra-indication to procarbazine, vincristine or lomustine including: coeliac disease; the rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption.
- •10. Any recognised genetic syndrome causing sensitivity to radiotherapy.
- •11. Patient unwilling/ unable to attend for follow up in the local radiotherapy centre.
- •12. Contraindication to MRI or gadolinium.
研究者
相似试验
招募中
不适用
Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)Brain TumorsNCT02824731Technische Universität Dresden555
招募中
不适用
The effect of different radiotherapy regimen on the immune cell landscapetumor10027656cancerNL-OMON52433Radboud Universitair Medisch Centrum200
尚未招募
不适用
Proton beam radiotherapy followed by Tecentriq(R) amd Avastin(R) for primary liver cancer with protal vein InvasioNeoplasmsKCT0008001Samsung Medical Center32
招募中
不适用
Randomized trial of radiotherapy with protons vs. radiotherapy with photons for patients with WHO grade II-III gliomaC71Malignant neoplasm of brainDRKS00015160Abteilung Klinische Neuroonkologie, Klinik für Neurologie, Universitätsklinikum Essen80
招募中
Unknown
Outcomes of carbon ion radiotherapy and photon stereotactic body radiotherapy using Cyberknife for uveal melanomauveal melanomaJPRN-UMIN000053540ational Institute for Quantum Science and Technology380